Results 171 to 180 of about 3,155,630 (345)
LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma
Molecular Oncology, EarlyView.The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico +12 morewiley +1 more sourceA genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer
Nature Genetics, 2007 D. Hunter, P. Kraft, K. Jacobs, D. Cox, M. Yeager, S. Hankinson, S. Wacholder, Zhaoming Wang, R. Welch, A. Hutchinson, Junwen Wang, Kai Yu, N. Chatterjee, N. Orr, W. Willett, Graham A Colditz, R. Ziegler, C. Berg, S. Buys, C. McCarty, H. Feigelson, E. Calle, M. Thun, R. Hayes, M. Tucker, D. Gerhard, J. Fraumeni, R. Hoover, G. Thomas, S. Chanock +29 moresemanticscholar +1 more sourceATF4‐mediated stress response as a therapeutic vulnerability in chordoma
Molecular Oncology, EarlyView.We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs +11 morewiley +1 more sourceA subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Molecular Oncology, EarlyView.Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli +3 morewiley +1 more sourceDeveloping evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more sourceMultiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes
Nature Genetics, 2018 R. Malik, G. Chauhan, M. Traylor, M. Sargurupremraj, Y. Okada, A. Mishra, L. Rutten-Jacobs, A. Giese, S. W. van der Laan, S. Gretarsdottir, C. Anderson, M. Chong, H. Adams, T. Ago, P. Almgren, P. Amouyel, H. Ay, Traci M. Bartz, O. Benavente, S. Bevan, G. Boncoraglio, Robert D. Brown, A. Butterworth, C. Carrera, C. Carty, D. Chasman, Wei-Min Chen, J. Cole, A. Correa, I. Cotlarciuc, Carlos Cruchaga, J. Danesh, P. D. de Bakker, A. Destefano, M. den Hoed, Qing Duan, S. Engelter, G. Falcone, R. Gottesman, R. Grewal, V. Gudnason, S. Gustafsson, J. Haessler, T. Harris, Ahamad Hassan, A. Havulinna, S. Heckbert, E. Holliday, G. Howard, F. Hsu, H. Hyacinth, M. Ikram, E. Ingelsson, M. Irvin, X. Jian, J. Jiménez-Conde, Julie A. Johnson, J. Jukema, M. Kanai, Keith L. Keene, B. Kissela, D. Kleindorfer, C. Kooperberg, M. Kubo, L. Lange, C. Langefeld, C. Langenberg, L. Launer, J. Lee, R. Lemmens, D. Leys, C. Lewis, Wei-Yu Lin, A. Lindgren, E. Lorentzen, P. Magnusson, J. Maguire, A. Manichaikul, P. McArdle, J. Meschia, B. Mitchell, T. Mosley, M. Nalls, T. Ninomiya, M. O’Donnell, B. Psaty, S. Pulit, Kristiina Rannikmäe, A. Reiner, K. Rexrode, K. Rice, S. Rich, P. Ridker, N. Rost, P. Rothwell, J. Rotter, T. Rundek, R. Sacco, S. Sakaue, M. Sale, V. Salomaa, B. Sapkota, R. Schmidt, C. Schmidt, U. Schminke, Pankaj Sharma, A. Słowik, C. Sudlow, C. Tanislav, T. Tatlisumak, K. Taylor, V. Thijs, G. Thorleifsson, U. Thorsteinsdóttir, S. Tiedt, S. Trompet, C. Tzourio, C. V. van Duijn, M. Walters, N. Wareham, S. Wassertheil-Smoller, James G. Wilson, K. Wiggins, Qiong Yang, S. Yusuf, J. Bis, T. Pastinen, A. Ruusalepp, E. Schadt, Simon Koplev, J. Björkegren, Veronica Codoni, M. Civelek, N. Smith, D. Trégouët, I. Christophersen, C. Roselli, S. Lubitz, P. Ellinor, E. Tai, J. Kooner, N. Kato, Jiang He, P. van der Harst, P. Elliott, J. Chambers, F. Takeuchi, Andrew D. Johnson, D. Sanghera, O. Melander, C. Jern, D. Strbian, I. Férnandez-Cadenas, W. Longstreth, A. Rolfs, J. Hata, D. Woo, J. Rosand, G. Paré, J. Hopewell, D. Saleheen, K. Stefánsson, B. Worrall, S. Kittner, S. Seshadri, M. Fornage, H. Markus, J. Howson, Y. Kamatani, S. Debette, M. Dichgans +170 moresemanticscholar +1 more sourcePARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi +13 morewiley +1 more source
